Saturday 17 October 2026
Export RYTM’s income statement to Excel — free account
Rhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024. In the quarter to June 2026, revenue grew 46.9%, EPS grew 2.67% and free cash flow grew 60.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
86.17
1.80
−2.05%
Follow RYTM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
31.74 | 27.22 | 36.66 | 38.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(832.15) | (133.79) | (273.97) | (251.36) | |
P/B ratio |
73.95 | 48.10 | 50.02 | 44.97 | |
Price to Tangible BV |
77.64 | 50.18 | 52.01 | 46.70 | |
EV/Sales |
30.36 | 25.65 | 34.61 | 36.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(69.15) | (46.62) | (56.77) | (57.51) | |
EV/FCF |
(48.31) | (33.77) | (40.76) | (40.85) | |
Quick Ratio |
3.00 | 3.63 | 3.92 | 4.31 | |
Current Ratio |
3.45 | 4.17 | 4.41 | 4.75 | |
Net Debt/EBITDA |
6.85 | 6.54 | 8.31 | 7.95 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.59 | 0.52 | 0.44 | 0.40 | |
Operating CF/Net income |
0.18 | 0.78 | 0.52 | 0.49 | |
Capex/Depreciation |
0.00 | 0.00 | (3.50) | (131.58) | |
Interest Coverage |
(10.69) | (11.42) | (10.20) | (11.10) | |
Research and Development Expense of Revenue |
60.95% | 69.41% | 73.41% | 89.72% | |
Selling, General and Administrative Expense of Revenue |
94.66% | 105.79% | 100.40% | 102.20% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
36.57% | 38.43% | 33.65% | 36.67% | |
Graham Net Nets |
0.03 | 0.04 | 0.04 | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.80%) | (3.60%) | (2.91%) | (3.07%) | |
Free Cash Flow Yield |
(1.98%) | (2.79%) | (2.32%) | (2.30%) | |
Revenue per Share |
1.04 | 0.88 | 0.88 | 0.77 | |
Operating CF per Share |
(0.13) | (0.65) | (0.39) | (0.40) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.60) | |
Free Cash Flow per Share |
(0.13) | (0.65) | (0.41) | (1.01) | |
Cash per Share |
4.82 | 5.01 | 5.99 | 6.28 | |
Shareholders Equity per Share |
3.17 | 3.50 | 4.16 | 4.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.17 | 3.50 | 4.16 | 4.46 | |
Free Cash Flow |
(9.15) | (44.18) | (26.34) | (66.62) | |
Working Capital |
302.98 | 326.89 | 360.97 | 390.54 | |
Capital Expenditures |
— | — | (0.95) | (40.00) | |
Net Current Asset Value |
206.60 | 225.39 | 256.75 | 283.61 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.78 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
33.27 | 26.01 | 22.30 | 26.17 | |
Average Payables |
16.07 | 12.11 | 13.14 | 9.26 | |
Average Inventory |
24.69 | 23.98 | 22.25 | 18.00 | |
Average Assets |
405.00 | 414.50 | 436.23 | 435.22 | |
Average Common Equity |
45.54 | 70.93 | 80.40 | 80.02 |
Columns are period end dates